Incidal-OD

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Incidal-OD

Property Description
Active ingredient Cetirizine Hydrochloride
Form Oral Capsule / Tablet (Once Daily)
Pharmacological class Second-Generation Antihistamine
Common use Relief of allergic symptoms
Origin Active metabolite of Hydroxyzine

Incidal-OD is a widely recognized brand-name medication containing the active ingredient cetirizine hydrochloride. This compound is classified as a highly selective, long-acting second-generation antagonist of the peripheral histamine H1-receptor. The medication is commonly supplied in an oral capsule or tablet form.

A key feature of this brand is the "OD" designation, which generally indicates an extended-release or "Once Daily" formulation. This reflects the medication’s long duration of action, which is recognized for supporting a single, daily dose for continuous 24-hour symptom relief.

Cetirizine is an active metabolite of the older antihistamine hydroxyzine. Unlike many first-generation drugs, it was designed to achieve anti-allergic efficacy with minimal penetration into the central nervous system (CNS), making it generally non-sedating. The mechanism of action involves blocking the effects of histamine, a substance in the body that causes allergic symptoms.

Furthermore, cetirizine is recognized for being effective and well-tolerated in the treatment of allergic conditions, serving as a therapeutic option for managing discomfort. This established safety and efficacy profile contributes to its status as a trusted, often Over-the-Counter (OTC), medication for continuous allergy management.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Incidal-OD?

Possible Side Effects and Safety Information

The safety profile of Incidal-OD (Cetirizine Hydrochloride) is officially documented by government regulatory bodies, classifying adverse reactions primarily by frequency and the body system affected. These classifications establish the medicine's risk profile, emphasizing that the majority of documented reactions are common or uncommon.

Regulatory Classification of Adverse Reactions

Adverse reactions are grouped based on the frequency observed in regulatory data:

Classification Examples of Reactions
Common (Reported ge 1/100 to <1/10) Somnolence (Drowsiness), Headache, Dry mouth, Fatigue, Nausea, Dizziness
Uncommon (Reported ge 1/1,000 to <1/100) Agitation, Abdominal pain, Rash, Pruritus (Itching)

These effects are largely associated with the Nervous System (e.g., drowsiness, headache) and Gastrointestinal System (e.g., dry mouth, nausea), as noted in System-Organ-Class groupings.

Serious Reactions and Safety Constraints

The regulatory safety profile explicitly documents rare but serious adverse reactions, including severe Hypersensitivity reactions (such as Anaphylactic shock) and Hepatitis. These reactions are classified as Very Rare or Rare.

Regulatory documentation establishes specific safety constraints. The medicine is contraindicated in individuals with known hypersensitivity to the drug or its parent compound (hydroxyzine), and those with severe renal impairment (kidney disease). Caution is also advised regarding the potential for enhanced central nervous system effects, particularly when used concurrently with alcohol or other CNS depressants. Furthermore, specific safety notes indicate that effects like drowsiness may be more noticeable at the start of therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Incidal-OD (Cetirizine Hydrochloride) overdose is documented based on exposures of at least 50 mg or five times the recommended daily dose. Symptoms observed are mainly associated with Central Nervous System (CNS) effects or effects suggesting an anticholinergic effect, which may range from mild drowsiness to profound stupor.

Category Documented Manifestations
CNS Effects Somnolence, Sedation, Stupor, Confusion, Dizziness, Tremor, Restlessness, Fatigue.
Other Effects Tachycardia (fast heart rate), Urinary retention, Diarrhea, Mydriasis (dilated pupils).

Required Emergency Actions

Immediate medical attention is required following a suspected overdose. The government labels instruct contacting a Poison Control Center or calling emergency services immediately if severe symptoms are present. Severe manifestations necessitating urgent help include collapse, seizure, trouble breathing, or inability to be awakened. Overdose may cause more severe symptoms in children and older adults, which is a population-specific consideration in regulatory documents.

Management and Antidote Status

No specific antidote is known for this substance. Management is focused on symptomatic and supportive treatment. Regulatory documents state that gastric lavage may be considered shortly after ingestion. Furthermore, the substance cannot be effectively removed by dialysis.

Therapeutic Uses of Incidal-OD

What Incidal-OD Treats: Main Uses and Benefits

Incidal-OD (Cetirizine Hydrochloride) is applied across therapeutic domains involving symptoms related to heightened physiological activity, providing supportive symptomatic relief for various allergic conditions. The medication is commonly used to help manage the disruptive manifestations of allergies.

The medication is applied in addressing conditions marked by increased physiological stress, such as seasonal allergic rhinitis (hay fever), perennial allergic rhinitis, allergic conjunctivitis, and chronic idiopathic urticaria (persistent hives). It is relevant for easing symptom clusters that may become intense or disruptive, including symptoms related to physical discomfort such as sneezing, runny nose, nasal itching, watery eyes, and generalized skin pruritus.

The medication is applied in scenarios where continuous symptomatic support is needed, such as in conditions characterized by recurrent or episodic manifestations. This assistance is applied when symptoms interfere with daily functioning, supporting a reduction in the overall symptom load.

“This medication is considered relevant in clinical settings associated with persistent allergic skin discomfort and nasal irritation, supporting stability when symptoms are more noticeable.”

It is relevant for managing symptoms that create noticeable physiological strain, which may assist patients with coping more steadily with difficult episodes.


Quick Fact: Relevant in conditions involving Persistent Itching (Pruritus) and Hives (Urticaria) manifestations.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Incidal-OD?

The population eligibility for Incidal-OD (Cetirizine Hydrochloride) is strictly defined by regulatory authorities and is based on age, hypersensitivity, and organ function.

Contraindicated and Restricted Populations

Classification Population Rule (Official Statement)
Absolute Contraindication Patients with known hypersensitivity to cetirizine, hydroxyzine, or any piperazine derivatives.
Absolute Contraindication Patients with severe renal impairment (Creatinine Clearance <10 mL/min).
Not Recommended Infants under 6 months of age for any indication.
Conditional Use Patients with moderate renal or hepatic impairment (requires assessment).
Conditional Use Pregnant or lactating women; use is recommended only if clearly needed.
Special Caution Patients predisposed to urinary retention or those at risk of convulsions.

Age-Related Eligibility

  • Approved: Adults and adolescents 12 years of age and older.
  • Pediatric: Children 6 years of age and older are eligible for oral tablet formulations.
  • Conditional: Use in older adults is contingent on maintaining normal renal function.

These rules establish the official population boundaries, mandating prohibition for severe kidney disease and allergy, while requiring caution for compromised organ function and specific comorbidities.

What should I know about interactions with other medicines?

The official regulatory profile for Incidal-OD (Cetirizine Hydrochloride) outlines interactions primarily through two mechanisms: pharmacodynamic potentiation and pharmacokinetic clearance alteration.

Official Interaction Statements:

  • Co-administration with alcohol and other Central Nervous System (CNS) Depressants may cause a pharmacodynamic potentiation, resulting in an additive reduction in alertness and impairment of CNS performance.
  • A specific pharmacokinetic interaction occurs with Theophylline (at a 400 mg once-daily dose), which leads to a 16% decrease in cetirizine clearance, thereby increasing cetirizine plasma exposure.
  • While food does not reduce the overall extent of the medicine's absorption, regulatory documents confirm the rate of absorption is delayed.
  • Cetirizine is also documented as a P-glycoprotein substrate, a point relevant for assessing the potential impact of co-administered P-gp inhibitors.
  • In patients with renal and/or hepatic impairment, the overall clearance of cetirizine is reduced, an important consideration for potential interaction outcomes and managing total drug exposure.

Interaction-Related Constraints:

The medicine has no formal drug-drug interaction contraindications listed in core regulatory labels. Restrictions are related to avoiding concurrent use with alcohol and CNS depressants due to the risk of additive impairment. No mandatory time-separation rules for co-administration are officially documented. The interaction profile is generally limited, reflecting the drug's low degree of CYP450 metabolism.

Mechanism of Action

How Incidal-OD Works

The mechanism of action for Incidal-OD (Cetirizine) is strictly focused on controlling specific signaling pathways at the cellular level to modulate the body's physiological responses.


Deactivating the Peripheral H1-Receptor

The core mechanism involves acting as a highly selective inverse agonist on the peripheral Histamine H1-receptor. This interaction stabilizes the receptor in its inactive state, directly disabling the primary molecular switch that histamine uses to generate a signal. This targeted action restricts the molecule’s H1-receptor modulation primarily to the peripheral system, reflecting its low permeability across the blood-brain barrier.


Modulating Vascular and Itch Signaling Cascades

By blocking H1-receptor activation on endothelial cells and sensory nerve endings, the drug suppresses downstream signaling cascades that govern fluid movement and sensation. This action preserves the structural integrity of the microvasculature, resulting in reduced extravasation of fluid, and inhibits the transmission of histamine-mediated nociception, which is a functional consequence of H1-receptor blockade on sensory nerve endings.


⏱️ Sustained Receptor Occupancy and Duration

The prolonged action profile over a 24-hour period is governed by its slow dissociation kinetics from the H1-receptor. This means the molecule stays bound to its target for an extended duration, ensuring sustained receptor deactivation and resulting in sustained modulation of the histamine pathway. This mechanism maintains pathway modulation even as the concentration of the drug in the bloodstream naturally decreases.

Dosage and Administration Information

Incidal-OD administration is based on the oral route, with the medicine provided in forms including tablets, capsules, and solutions. The product's designation as "OD" reflects its long duration of action, supporting its standard administration pattern. The standard daily regimen for adults and adolescents aged 12 years and older is 10 mg taken once every 24 hours. This is the maximum recommended dose for a single daily intake. For less severe symptoms, the dose may be initiated at 5 mg once daily.

The medicine may be taken with or without food, providing flexibility in scheduling the intake. Tablets should be swallowed whole with a liquid. If a dose is missed, it should be taken as soon as the lapse is noticed, unless the time for the next scheduled dose is near, in which case the missed dose should be skipped; double-dosing is strictly advised against.

The established dosing patterns require modification for certain patient groups. For children between 6 and 12 years of age, the total daily amount of 10 mg is commonly administered as a divided dose of 5 mg twice daily.

A dose reduction is also required for patients who have reduced kidney function (renal impairment) to prevent accumulation of the active substance; the adjustment is based on the severity of the impairment. These descriptions represent the standardized approach to using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Incidal-OD


Evidence for Use in Seasonal and Perennial Allergies (Rhinitis)

The research base for Incidal-OD (cetirizine) primarily includes Randomized Controlled Trials (RCTs), a foundational study type used to evaluate new medicines. These studies, many of which were double-blind and compared the medicine against a placebo (a non-active pill) or to other allergy medications, were used in research exploring measures of symptom change in individuals with hay fever (seasonal) and year-round allergies (perennial rhinitis). Studies monitored outcomes related to physical discomfort, specifically tracking changes in symptoms like sneezing, runny nose, nasal itching, and watery eyes. Long-standing evidence contributes to the broader evidence landscape, and the medicine is often used as an active comparator drug in research studying other second-generation antihistamines. Comparative evidence is lacking regarding the precise onset of action when compared to some newer similar medicines.


Evidence for Use in Chronic Hives (Chronic Idiopathic Urticaria)

Research has also examined the role of Incidal-OD in conditions characterized by fluctuating or episodic manifestations such as chronic hives (Chronic Idiopathic Urticaria). Studies conducted during periods of heightened symptom activity used randomized trials and systematic reviews to examine the effect on symptoms like persistent itching and the appearance of hives (wheals). The findings describe patterns observed in these studies, leading to the medicine's inclusion in current clinical treatment guidelines. High-quality data from large RCTs are limited regarding the use of doses exceeding the standard licensed dose, even in cases where symptoms become more noticeable.


Research on Study Duration and Long-Term Follow-up

The core data for Incidal-OD primarily derives from short-term and intermediate-term studies. Core efficacy trials typically observed responses over defined time intervals ranging from as short as one week up to six weeks. Research describes some long-term data for specific groups, such as pediatric prevention studies that evaluated children, which have included observational follow-up periods extending up to several years.

Key Studies & References

  1. Cetirizine for the treatment of allergic diseases in children: A systematic review and meta-analysis
  2. Study Details: Comparing Standard-Dose and High-Dose Cetirizine for Acute Urticaria (NCT07236372)

Frequently Asked Questions (FAQ)

Common questions about Incidal-OD (FAQ)


Q: Is Incidal-OD the same as cetirizine?

A: Incidal-OD is a brand name medication that contains the active ingredient cetirizine hydrochloride. Official drug information confirms that cetirizine is the substance responsible for the medication's intended effects.

Q: Does Incidal-OD affect your stomach?

A: The official regulatory safety profile reports that this medicine may affect the gastrointestinal system. Specifically, nausea is listed as a common reaction, and abdominal pain is documented as an uncommon reaction associated with its use.

Q: Can Incidal-OD cause changes in mood?

A: Regulatory documents report adverse reactions linked to the nervous system, which include uncommon reactions such as agitation. In very rare instances, reports have included reactions like hallucinations.

Q: Is Incidal-OD safe to use while breastfeeding is listed in official documents?

A: Official regulatory documents confirm the medicine is excreted in breast milk. Its use during lactation is generally not recommended. Conditional use is described in regulatory documents, recommending it only if clearly needed.

Q: How is Incidal-OD different from a regular antihistamine tablet?

A: This medication is classified as a second-generation antihistamine. This category of medicine is described as having highly selective action which reflects its low potential for central nervous system effects, leading to its description as generally non-sedating compared to some older antihistamines.

Q: Is Incidal-OD a steroid?

A: No, official documents classify the medicine as a second-generation antihistamine. It works as an antagonist on the peripheral H1-receptor (a type of cell switch for histamine) and is not categorized as a steroid.

Q: Can Incidal-OD be used for treating a common cold?

A: The official documented uses for this medicine are primarily for the relief of allergic symptoms, such as those associated with seasonal and perennial rhinitis (hay fever or year-round allergies), and for chronic hives (urticaria). The treatment of the common cold is not an explicitly documented use.

Q: What is known about Incidal-OD and liver function?

A: Rare cases of Hepatitis have been documented as a serious adverse reaction. Additionally, use requires conditional assessment in patients with impaired liver function, which is an important consideration due to the medicine’s reduced clearance in these individuals.

Q: Are there different strengths of Incidal-OD available?

A: Official regulatory documents define standard daily dosing in 10 mg and 5 mg amounts. These amounts correspond to the doses available in marketed products.

Q: How quickly does Incidal-OD start working?

A: Official information indicates the time required to reach the maximum concentration in the bloodstream (pharmacologically known as T max) is approximately one hour following oral administration in adults.

Q: Are there any common foods or drinks to avoid while using Incidal-OD?

A: Official data indicates that while consuming food may delay the rate of absorption, it does not reduce the overall amount absorbed by the body. However, the concurrent use of alcohol is restricted in official documents due to the risk of additive sedation.

Q: Does Incidal-OD interact with common pain relievers like paracetamol or ibuprofen?

A: Regulatory documentation does not list specific, clinically significant interactions with common pain relievers, such as ibuprofen or paracetamol (acetaminophen).

Q: Why do some people take Incidal-OD at night?

A: Although the medicine is generally non-sedating, the safety profile lists drowsiness as a common reaction. If a person experiences this side effect, the medicine may be scheduled for evening intake to manage potential daytime impairment if drowsiness is experienced.

Q: Does Incidal-OD lose effectiveness over time?

A: Regulatory warnings describe a risk of severe itching (pruritus) upon stopping the medicine after long-term use. Official documents do not report a loss of effectiveness associated with continuous use.

Q: What should I do if I experience a side effect mentioned on the leaflet?

A: Official regulatory bodies describe that all suspected side effects, especially those that are unexpected or serious, are to be reported to a healthcare professional or the national drug safety surveillance program.

Q: What is the general guidance on stopping the use of Incidal-OD?

A: Recent safety updates by regulatory bodies warn about the potential for rare but severe itching (pruritus) upon stopping the medicine following long-term daily use. This is a potential reaction to be aware of when discontinuing therapy.

Q: Does Incidal-OD have a 'rebound' effect if you stop taking it?

A: Regulatory documents have reported cases of severe itching (pruritus) upon discontinuation of long-term use. Reports indicate the symptoms have been documented to improve when the medicine is restarted.

Q: Does Incidal-OD contain any lactose or gluten?

A: Regulatory documents for some brand-name formulations indicate the presence of lactose monohydrate in the inactive ingredients. Information regarding the presence of gluten is typically not specified in the core product labels.

Q: What is the official recommended maximum duration of use for Incidal-OD?

A: Official documents state that the duration of treatment may vary depending on the specific allergic symptoms being addressed. Regulatory bodies generally do not specify a single maximum duration limit for all uses.

Q: Are there any specific heart-related cautions listed for Incidal-OD?

A: Regulatory studies have demonstrated that the medicine is generally devoid of QTc prolongation effects (a measure of heart rhythm) and cardiac toxicity, which reflects its profile as having a low potential for severe cardiovascular effects.

Q: What are the general considerations for people with certain eye conditions, like glaucoma, and Incidal-OD?

A: The official prescribing information advises caution due to a potential for urinary retention in susceptible patients. Antihistamines, in general, are sometimes advised for caution in patients with specific forms of glaucoma.

Q: Does Incidal-OD affect blood pressure?

A: Regulatory documents report rare instances of low blood pressure as an adverse reaction. Studies suggest the medicine has minimal anticholinergic effects and does not typically compromise hypertension management.

Q: Is there a link between Incidal-OD and weight changes?

A: Research suggests that the use of H1 antihistamines has been associated with higher body weight and BMI in some populations. There are also indications that these medicines may stimulate appetite.

Q: Is Incidal-OD classified as a prescription-only or over-the-counter medicine?

A: The medicine is generally available in both prescription and over-the-counter (OTC) forms. However, its official status and available strengths may vary depending on the country or region.

Q: Are there any reported interactions between Incidal-OD and herbal supplements?

A: Government health guidance advises caution with herbal remedies and supplements that may cause side effects like sleepiness or dry mouth. This is because concurrent use with the medicine may contribute to these effects.

Q: What official documents describe the ingredients of Incidal-OD?

A: Regulatory documents such as the DailyMed Label (in the US) contain detailed information regarding both the active and inactive ingredients of the medicine's various available formulations.

How should Incidal-OD be stored and disposed of?

How to Store and Dispose of Incidal-OD?

Regulatory documentation mandates specific conditions to maintain the stability of Incidal-OD (Cetirizine Hydrochloride) and ensure proper safety and disposal.

Official Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at controlled room temperature (typically 20 to 25 C) and keep from freezing.
Environment Protect from excess heat and moisture; do not store in the bathroom.
Container Keep the medication in the original container, tightly closed.
Safety It is mandatory to keep out of the sight and reach of children and to lock safety caps.

Disposal Instructions

Expired or unused Incidal-OD must be discarded according to local, state, and federal regulations. To protect the environment, the medicine should not be released into wastewater or drains. Patients are advised to consult a healthcare professional or pharmacist for specific instructions on disposal at an approved waste collection site.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Incidal-OD found in:

A-Z Index: